Committee hears competing testimony on bill to require fertility coverage for state and employer plans

The House Health Care & Wellness Committee heard Jan. 21 on House Bill 1129, legislation that would require large and small group health plans — and, to specified extents, Medicaid and state employee plans — to cover fertility preservation services and, beginning in 2027, diagnosis and treatment for infertility consistent with professional guidelines.

Committee staff summarized the bill’s requirements. "Standard fertility preservation services are the procedures that are consistent with established practices or professional guidelines published by the American Society of Reproductive Medicine or the American Society of Clinical Oncology," Kim Weidner told the committee, adding that the bill would require coverage of two oocyte retrievals with unlimited embryo transfers in accordance with ASRM guidelines for plans issued or renewed on or after Jan. 1, 2027.

Supporters included patients, clinicians and advocacy groups who described the emotional and financial burden of infertility and urged the state to expand access. Multiple witnesses recounted medical scenarios that left them infertile or unlikely to conceive without assisted reproductive technologies. Erica Sahota told the committee she needed IVF after genetic testing revealed a heritable condition and described paying roughly $30,000 for testing and treatment. Miranda Thehey described emergency surgery after an ectopic pregnancy that left her unable to conceive without IVF. Cancer clinicians emphasized fertility preservation for patients facing sterilizing treatments: "Cancer and other medical conditions can take so much from a young person, but it does not need to steal their ability to be a mother or father someday," said Dr. Tyler Ketrell of Seattle Children's, who urged coverage of preservation for patients at risk of infertility from treatment.

Representatives of insurers and the Office of the Insurance Commissioner urged caution about cost and scope. Jane Beyer of the OIC explained federal Affordable Care Act interactions and noted that, because the legislation limits the mandate to group plans, the requirement may not trigger the ACA's qualified health plan defrayal provisions for the individual market; she requested follow‑up on federal interpretation. Christine Brewer of Premera Blue Cross said the carrier's actuarial analysis estimated a per member per month premium increase of $7.68 for the bill as written, which she described as about a 1.4% premium impact in Premera's portfolio; earlier actuarial work by Milliman cited lower estimates (roughly $4–$5 PMPM) depending on covered services.

Opponents raised moral and fiscal objections. Speakers from the Conservative Ladies of Washington and other groups objected on ethical grounds to embryo creation and potential disposal, and argued the mandate would raise premiums and taxpayer costs. Teresa Schrempp testified in opposition, citing high average costs per IVF episode and objections to funding procedures she described as involving embryo destruction.

Advocates urged lawmakers to weigh long‑term clinical and equity benefits against the near‑term premium impacts. Supporters noted that other states have enacted similar mandates and that public employers such as King County offer fertility benefits as an employee retention and equity measure. Several clinicians and patient advocates emphasized the particular importance of preservation coverage for young people undergoing cancer treatment.

The committee heard extensive personal testimony and technical questions about federal law, benefit design, and actuarial cost estimates. No vote was taken; members indicated further work with stakeholders would be needed.